Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Treasury Shares (2019 - 2026)

C4 Therapeutics has reported Treasury Shares over the past 7 years, most recently at $4.5 million for Q1 2026.

  • For Q1 2026, Treasury Shares changed N/A year-over-year to $4.5 million; the TTM value through Mar 2026 reached $4.5 million, changed N/A, while the annual FY2025 figure was $2.8 million, 2776.28% up from the prior year.
  • Treasury Shares for Q1 2026 was $4.5 million at C4 Therapeutics, up from $2.8 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.5 million in Q1 2026 and troughed at $6634.0 in Q3 2024.
  • A 5-year average of $1.3 million and a median of $687140.0 in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: tumbled 99.12% in 2024 and later skyrocketed 43183.48% in 2025.
  • Year by year, Treasury Shares stood at $468316.0 in 2022, then tumbled by 67.12% to $154000.0 in 2023, then crashed by 36.36% to $98000.0 in 2024, then surged by 2776.28% to $2.8 million in 2025, then surged by 58.48% to $4.5 million in 2026.
  • Business Quant data shows Treasury Shares for CCCC at $4.5 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.